IP Library › Granted Patent US 8,580,921
Granted Patent B2
US 8,580,921 · App. 13/548,947 · Granted Nov 12, 2013

Protein nanorings

Inventor: Carston R. Wagner (Saint Paul, MN)
Assignee: University of Minnesota
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,580,921
App. No.
13/548,947
Granted
Nov 12, 2013
Kind
B2
Abstract

The invention provides protein nanorings.

Claims (26)

1. An oligomer comprising

a first fusion protein comprising a first DHFR molecule linked to a second DHFR molecule by an amino acid linker, and an scFv linked to one of the DHFR molecules by an amino acid linker; and

a conjugate comprising a first methotrexate molecule linked to a second methotrexate molecule, and a therapeutic agent linked to the conjugate,

wherein the first fusion protein is non-covalently bound to the conjugate.

2. The oligomer of claim 1 , wherein the oligomer is capable of self-assembly.

3. The oligomer of claim 1 , wherein the amino acid linker linking the first DHFR molecule to the second DHFR molecule is 1 to 13 amino acids in length.

4. The oligomer of claim 1 , wherein the amino acid linker linking the first DHFR molecule to the second DHFR molecule is 1 to 3 amino acids in length.

5. The oligomer of claim 1 , wherein the amino acid linker linking the first DHFR molecule to the second DHFR molecule is 1, 3, 7, or 13 amino acid in length.

6. The oligomer of claim 1 , wherein the scFv is anti-CD3.

7. The oligomer of claim 1 , wherein the therapeutic agent is an anticancer agent.

8. The oligomer of claim 7 , wherein the anticancer agent is doxorubicin or auristatin or a radiotherapeutic agent.

9. The oligomer of claim 1 , wherein the therapeutic agent is an antiviral agent.

10. The oligomer of claim 1 , wherein the therapeutic agent is methotrexate.

11. The oligomer of claim 1 , wherein the first methotrexate molecule is linked to the second methotrexate molecule by a methylene linker.

12. The oligomer of claim 11 , wherein the methylene linker is 9 or 12 carbon atoms in length.

13. The oligomer of claim 1 , wherein the first methotrexate molecule is linked to the second methotrexate molecule by a polyamine linker.

14. The oligomer of claim 1 , wherein the polyamine linker is 11 atoms in length.

15. The oligomer of claim 1 , wherein the therapeutic agent is linked to the conjugate by a polyethylene glycol (PEG) linker.

16. The oligomer of claim 15 , wherein the therapeutic agent is linked to the PEG linker by a lysosomal protease sensitive spacer.

17. The oligomer of claim 1 , wherein the oligomer is disassembled by trimethoprim.

18. An oligomer comprising

a first fusion protein comprising a first DHFR molecule linked to a second DHFR molecule by an amino acid linker, and an scFv linked to one of the DHFR molecules by an amino acid linker; and

a conjugate comprising a first methotrexate molecule linked to a second methotrexate molecule, and a detectable group linked to the conjugate,

wherein the first fusion protein is non-covalently bound to the conjugate.

19. The oligomer of claim 18 , wherein the detectable group is a fluorophore.

20. The oligomer of claim 19 , wherein the fluorophore is Alexa Fluor 488.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 14, 2014
From: REGENTS OF THE UNIVERSITY OF MINNESOTA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032449/0427 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2012
From: WAGNER, CARSTON R.
To: UNIVERSITY OF MINNESOTA
Reel/Frame 029174/0514 →
Continuity (3)
Continuation 11511186 · Aug 28, 2006
Provisional Application 60711563 · Aug 26, 2005
Related Publication 20130059359A1 · Mar 7, 2013